RPG Life Sciences Ltd Guidance Report - SOIC x StockScans Report
as of Nov 2026
- FY22 dividend - ₹9.60 (120%) per share
Delivered - In the FY22 annual report, the Directors recommended a dividend of ₹9.60 (120%) per share. The recommendation of ₹9.60 (120%) stands as stated in the same report.
- FY26 dividend - 300%
Delivered - At the Q4 FY26 announcement, management noted a recommended dividend of 300%. The dividend of 300% was recommended as stated.
- FY25 dividend - 250% plus 50% special
Delivered - The Board recommended the highest-ever dividend of 250% plus a special dividend of 50% on face value of Rs. 8 each for FY25, subject to shareholder approval. FY26 saw a recommended dividend of 300%; no explicit payment confirmation for FY25 is in our record.
- Gastro and Derma entry - replicating Rheumatology strategy
Pending - Management said it was working on replicating the Rheumatology portfolio entry strategy to enter specialties like Gastro and Derma as future growth drivers of Domestic Formulations. No explicit Gastro or Derma entry confirmation appears in our record.
- Specialty therapies expansion - Nephrology, Rheumatology, Gastroenterology, Oncology
Delivered - In the FY21 annual report, management aimed to grow Specialty therapies (Nephrology, Rheumatology, Gastroenterology, Oncology) and Chronic therapies, with new Rheumatology launches planned. FY26 therapy growth reached Nephrology 55.2%, Rheumatology 40.2%, Oncology 23.2%, and a new rheumatology franchise contributes 14% to the specialty business.
- International Formulations - emerging markets expansion (Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan)
On track - In the FY22 annual report, the company intended to expand its International Formulations footprint in Myanmar, Vietnam, Philippines, Sri Lanka, Egypt and Sudan, with registrations worked out. IF sales grew 18.3% in FY23, 15% in FY24, 24% in FY25, then declined 6.7% in FY26; Q2 FY27 sees forays into 13 new markets.
- DF top 50 ranking - retain and improve
Delivered - At Q2 FY27, management aimed for domestic formulations to retain its top 50 position. RPGLS entered the Top 50 Pharma Company list in June'26, improving from rank 62 in March 2025 to rank 50 in Sep'26.
- International Formulations - 13 new markets, 3 R&D partnerships
On track - At Q2 FY27, management said international formulations are making forays into 13 new markets, with tie-ups with 3 R&D players to buy MAs and dossiers. The forays and tie-ups stand as stated, with 2 tenders already won and 75+ partner discussions held at CPHI, though double-digit growth is only expected from H2 FY27.
- EBITDA margin - 24.5% aspiration
On track - At Q2 FY27, management called FY25's 24.5% EBITDA margin "the aspiration", noting the company is at 24% and "we should reach there". FY26 EBITDA margin was 24.4% and H1 FY27 adjusted EBITDA margin 24.0%.
- Capex - below 7-8% of sales
Pending - At Q2 FY27, the CFO said capex remains planned except for acquired assets and will be below 7-8% of sales. CWIP moved from 16.06 in FY25 to 23.29 in FY26 and 20.44 at n/a; no FY27 capex-to-sales ratio is disclosed yet.
- DF supply-challenge recovery - ₹5-5.5 cr sales recovery, \~15% primary growth
On track - At Q2 FY27, management expected to recover ₹5-5.5 cr of sales lost to third-party supply challenges, returning DF to \~15% primary growth; growth would have been 15.2% without the impact. Supply issues cleared in October with some September-lost sales recovered, and Q2 DF grew 11.6%.
- Semaglutide launch - GLP-1 entry
Delivered - At Q2 FY27, management aimed to scale new launches including semaglutide in domestic formulations. Semaglutide injections launched in October across nephrology and cardiology divisions, marking GLP-1 entry.
- Naprosyn Canada - supply start mid-December 2026, 25-30% market share
Pending - At Q2 FY27, management said Naprosyn Canada supplies start by mid-December following social audit approval, expecting at least 25% to 30% market share to start with. Approval was received about a week before the call, after the 2025 ANDA approval in Canada; no shipment or share actuals yet.
- International Formulations - data-led R&D roadmap, ₹25 cr by FY30
Pending - At Q2 FY27, management has built a data-led R&D roadmap targeting about ₹25 cr by FY30 for international formulations. No read yet; the FY30 horizon is not reached.
- International Formulations - CDMO projects, ₹8 cr from FY29 UK
Pending - At Q2 FY27, management completed its first CDMO project on time, expected to add about ₹8 cr from FY29 in the UK, alongside about ₹10 cr from FY29 from Chile and Ethiopia tender wins. The project is complete with 3 more products to develop and tenders won in LATAM and Ethiopia; no FY29 revenue actuals yet.
- Domestic Formulations - 1.5x market growth
On track - At Q2 FY27, management reiterated the aspiration of 1.5x market growth for domestic formulations, committing "we will be above 1.5 in the coming quarters". Q2 DF grew 11.6% vs market \~9.8% and H1 FY27 DF grew 13.0%, 1.2x faster than market; FY26 DF grew 13.7% vs IPM 8.6%, \~1.6X.
- RPG Active Pharma - InvAscent investment, ₹243 cr initial raise
On track - RPG Active Pharma was to raise up to ₹243 crore from InvAscent-managed funds, with completion expected within 120 days from 29th July 2026, alongside the API business sale of \~₹33.55 cr by 30th September 2026. The API transfer was effective 14th August and a ₹700 crore committed capital pool was created; no explicit ₹243 cr completion confirmation yet.
- API acquisitions - Actis Generics and Raghava, ₹25-30 cr H2 FY27 revenue, mid-20s EBITDA
On track - At Q2 FY27, management guided acquired API entities' EBITDA "will be in mid-20s" and top line of ₹25-30 cr for H2 FY27. Both acquisitions closed end September 2026, contributing only ₹50 lakhs in Q2 with full revenue from Q3.
- API - third growth engine, 25%+ CAGR over 5 years
On track - At Q2 FY27, management reiterated 25%+ CAGR in API over the next 5 years, raising guidance to at least 30% over 3 to 5 years including inorganic, implying ₹300-350 cr by FY30 and ₹500 cr by FY32. Q2 FY27 API grew 85.5% to ₹27.5 cr and H1 FY27 API ₹54.6 cr, +58.5%, with Actis Generics and Raghava acquisitions completed.
- International Formulations - second growth engine, double-digit growth
On track - Management positioned International Formulations as the second growth engine, committing at Q2 FY27 to double-digit growth from H2 itself. H1 FY27 IF sales were ₹71.7 cr, +7.0%, after FY26 declined 6.7%, with tender wins and 3 additional CDMO products as drivers.
- Plant modernization and capacity expansion - \~2X capacity, \~₹140 cr capex
On track - From the Q4 FY24 PPT, management committed state-of-the-art plants with \~2X higher capacity, later tied to \~₹140 cr capex infusion. ₹185+ cr has been infused since FY22, modernization is underway at F1 and F2, EU/TGA/PMDA approvals are in place, and no explicit \~2X capacity confirmation is disclosed.
- Immunosuppressants - ₹100 cr portfolio, potential ₹200 cr
On track - At the Q4 FY24 PPT, management set the goal of a ₹100 cr immunosuppressants franchise via 12 variants and 4 new customer segments, raised at Q4 FY26 to a project growing the portfolio to 200+ crores. The FY25 annual report cites "Immunosuppressant a ₹100 crores portfolio" as a strategic asset; no further quantitative read on the ₹200 cr trajectory is in our record.
- Naprosyn - ₹100 cr mega brand
Partial - At the Q4 FY24 PPT, management set Goal 1: Naprosyn to become a ₹100 Cr mega brand, later extended to "future 500 cr OTC". Naprosyn crossed ₹100 cr in secondary sales on MAT basis, with H1 FY27 primary sales ₹47.9 cr, up 13.6%; no primary-sales ₹100 cr milestone is yet disclosed.